News headlines about Alcobra (NASDAQ:ADHD) have trended somewhat positive this week, according to Accern Sentiment Analysis. The research firm identifies positive and negative media coverage by reviewing more than twenty million news and blog sources in real-time. Accern ranks coverage of companies on a scale of negative one to one, with scores closest to one being the most favorable. Alcobra earned a news sentiment score of 0.14 on Accern’s scale. Accern also assigned media headlines about the biotechnology company an impact score of 44.5211417070532 out of 100, indicating that recent media coverage is somewhat unlikely to have an impact on the company’s share price in the immediate future.
These are some of the news stories that may have impacted Accern’s scoring:
- Alcobra Ltd. (ADHD) Given Consensus Rating of “Hold” by Analysts (americanbankingnews.com)
- Arcturus Therapeutics, Inc. to Present at the Chardan Gene Therapy … – Markets Insider (markets.businessinsider.com)
- Alcobra Ltd. (ADHD)- Deliverance of Ownership on Performance – Wallstreet Investorplace (wallstreetinvestorplace.com)
- Arcturus Therapeutics, Inc. to Present at the Chardan Gene Therapy Conference (finance.yahoo.com)
- Healthcare Stock is Neither buy nor sell: Alcobra Ltd. (ADHD) – Street Observer (press release) (streetobserver.com)
Alcobra (ADHD) opened at 1.05 on Friday. The firm’s market cap is $28.94 million. The stock has a 50 day moving average of $1.05 and a 200 day moving average of $1.11. Alcobra has a one year low of $0.83 and a one year high of $2.68.
Alcobra (NASDAQ:ADHD) last released its quarterly earnings results on Friday, August 11th. The biotechnology company reported ($0.13) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.15) by $0.02. On average, equities analysts forecast that Alcobra will post ($0.50) earnings per share for the current year.
Several research analysts have recently issued reports on the stock. Roth Capital cut shares of Alcobra from a “buy” rating to a “neutral” rating and lowered their target price for the company from $4.00 to $1.00 in a report on Friday, September 29th. Zacks Investment Research cut shares of Alcobra from a “buy” rating to a “hold” rating in a report on Tuesday, August 1st. Finally, Jefferies Group LLC restated a “hold” rating and issued a $1.25 target price on shares of Alcobra in a report on Monday, June 12th. Two investment analysts have rated the stock with a sell rating, seven have issued a hold rating and one has assigned a buy rating to the company. The stock presently has a consensus rating of “Hold” and a consensus target price of $1.55.
TRADEMARK VIOLATION NOTICE: This piece was reported by Transcript Daily and is the property of of Transcript Daily. If you are accessing this piece on another site, it was illegally stolen and reposted in violation of U.S. and international copyright law. The legal version of this piece can be read at https://transcriptdaily.com/2017/10/08/alcobra-adhd-receives-news-impact-rating-of-0-14.html.
Alcobra Ltd is a development-stage biopharmaceutical company. The Company is focused on development and commercialization of its lead product candidates, including MDX and ADAIR. MDX is a oral drug, for the treatment of ADHD and other cognitive disorders, including Fragile X. MDX is a combined rapid onset ER formulation of the chemical pyridoxine pyroglutamate, which is more commonly known as metadoxine.
Receive News & Ratings for Alcobra Ltd. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alcobra Ltd. and related companies with MarketBeat.com's FREE daily email newsletter.